Glucagon-like peptide 1 immunoreactivity in gastroentero-pancreatic endocrine tumors: a light- and electron-microscopic study

Abstract

The preproglucagon gene encodes, in addition to glucagon, two smaller peptides with structural similarity: glucagon-like peptides 1 and 2. Glucagon-like peptide 1 (GLP-1) 7-36 amide is the most powerful incretin candidate. In the present study, GLP-1 immunoreactivity was investigated in tissue specimens of various types of gastroenteropancreatic tumors, and the serum-levels of GLP-1 were assayed. Immunohistochemical staining of 88 tumors revealed GLP-1 immunoreactivity in 17 neoplasias (19.3%), viz., in 7 out of 33 non-functioning tumors, 4 out of 20 gastrinomas, 4 out of 13 insulinomas, 1 out of 3 vasoactive-intestinal-polypeptide (VIP)omas and 1 adrenocorticotropic-hormone (ACTH)-producing tumor. In these tumors, GLP-1-immunoreactive cells were distributed either diffusely, arranged in clusters, or as single cells. All GLP-1-positive tumors were immunoreactive for glucagon or glicentin, 10 tumors were immunoreactive for pancreatic polypeptide, and 8 tumors for insulin. Ultrastructural analysis of 8 GLP-1-positive tumors, with the immunogold technique, demonstrated GLP-1 immunoreactivity mainly in cells resembling the A-cells of the pancreas or the L-cells of the gut. Of the 17 GLP-1-immunoreactive tumors, 15 were primarily located in the pancreas. Additionally, 2 non-functioning tumors of the rectum were GLP-1 immunoreactive. Five tumors were GLP-1 immunoreactive from 9 patients with multiple endocrine neoplasia I syndrome. Patients with GLP-1-immunoreactive tumors were characterized by a significantly lower rate of distant metastases (P < 0.01) and a higher rate of curative resections (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Glucagon-like peptide-1 (GLP-1): A gut hormone of potential interest in the treatment of diabetes

“…(68) One interesting feature of the GLP-1 positive tumors is that they seem to exhibit a lower rate of distant metastases and a higher rate of curative resections. (68) The relevance of this finding for tumor biology remains to be established, however.…”

Novel application of hydrophobin in medical science: a drug carrier for improving serum stability

“…GLP-1, which was discovered in 1990, is a gut hormone released from intestinal L cells following oral glucose administration 1 . The function of GLP-1 is to stimulate the secretion of insulin, which balances abnormal blood glucose levels 2 3 4 5 6 . Compared with the administration of insulin directly, GLP-1 is an intelligent approach to achieve blood glucose control in a blood glucose level-dependent manner in which GLP-1 stimulates the secretion of insulin based on increased glucose levels.…”

Myricetin: a potent approach for the treatment of type 2 diabetes as a natural class B GPCR agonist

“…GLP-1 was discovered in 1990 and is gut hormone that is released from intestinal L cells after oral glucose administration (12). The function of GLP-1 is to stimulate the secretion of insulin, which balances abnormal blood glucose levels (13)(14)(15)(16)(17). Compared with the direct administration of insulin, GLP-1 is an intelligent approach to achieving blood glucose control in a blood glucose level-dependent manner because GLP-1 stimulates the secretion of insulin based on increased glucose levels.…”